Global Endometrial Cancer Market Size, Share, Forecast Report, 2020-2027

The abnormal growth of endometrium cells in the uterus is termed as endometrial cancer which is also known as uterine cancer. Endometrial cancer is diagnosed at an early stage as women experience abnormal vaginal bleeding. It is reported that endometrial cancer is the sixth most common cancer in women all over the world. The endometrial cancer market is expected to witness a tremendous growth owing to the rising prevalence of endometrial cancer. Other key factors such as the growing obesity among women, increase in menopausal hormone therapy, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian tumor are contributing towards the growth of the market. Diabetes is another risk factor that leads to the development of endometrial cancer. According to the American Cancer Society, endometrial cancer is four times common in diabetic women than in normal women. Such factors contribute to endometrial cancer among women.

However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.
Segmentation

The global endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user. The endometrial cancer market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, endometrial biopsy, dilation and curettage (D&C), and laparoscopy. On the basis of treatment, the market is segmented into hysterectomy techniques, radiation, hormone therapy, chemotherapy, and palliative care. The hysterectomy techniques category includes open abdominal hysterectomy, total vaginal hysterectomy, total laparoscopic hysterectomy, and robotic hysterectomy. The radiation category includes external radiation and internal radiation (brachytherapy). The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors. The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin, and cisplatin. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.
Key players

Some of the key players in the global endometrial cancer market are Pfizer Inc., General Electric Company, Koninklijke Philips N.V., LUPIN, PHYTON, Bayer AG, Celgene Corporation, Johnson & Johnson, CooperSurgical Inc., LiNA Medical USA, Conceptus Inc., Hologic Inc., Karl Storz GmbH & Co. Kg, and Boston Scientific Corporation.

Global Endometrial Cancer Market, by Diagnosis

• Pelvic examination
• Transvaginal ultrasound
• Endometrial biopsy
• Dilation and curettage (D&C)
• Diagnostic laparoscopy

Global Endometrial Cancer Market, by Treatment

• Hysterectomy Techniques
  • Open abdominal hysterectomy
  • Total vaginal hysterectomy
  • Total laparoscopic hysterectomy
  • Robotic hysterectomy
• Radiation
  • External radiation
  • Internal radiation (brachytherapy)
• Hormone therapy
  • Progestins
  • Tamoxifen
  • Luteinizing hormone-releasing hormone agonists
  • Aromatase inhibitors
• Chemotherapy
  • Paclitaxel
  • Carboplatin
  • Doxorubicin
  • Cisplatin
• Palliative care

Global Endometrial Cancer market, by End-User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Diagnostic Centers
• Gynecology Centers
• Feminist Health Centers

Global Endometrial Cancer Market, by Region

• The Americas
• Europe
• Asia-Pacific
• The Middle East & Africa

Global Endometrial Cancer Market, by Key Players

• Pfizer Inc.
• General Electric Company
• Koninklijke Philips N.V.
• LUPIN, PHYTON
• Bayer AG
• Celgene Corporation
• Johnson & Johnson
• CooperSurgical Inc.
• LiNA Medical USA
• Conceptus Inc.
• Hologic Inc.
• Karl Storz GmbH & Co. Kg,
• Boston Scientific Corporation